SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 124 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.54 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,312,948 | -31.3% | 297,035 | -0.9% | 2.89% | -32.0% |
Q2 2023 | $6,275,672 | -10.0% | 299,841 | -9.1% | 4.25% | -17.2% |
Q1 2023 | $6,969,600 | -15.6% | 330,000 | +1.7% | 5.13% | +1.0% |
Q4 2022 | $8,261,426 | +5.9% | 324,614 | 0.0% | 5.08% | +51.4% |
Q3 2022 | $7,800,000 | +97.8% | 324,614 | +58.3% | 3.36% | +52.9% |
Q2 2022 | $3,944,000 | +10.1% | 205,003 | -0.5% | 2.20% | +31.2% |
Q1 2022 | $3,582,000 | -20.6% | 206,126 | 0.0% | 1.67% | -11.8% |
Q4 2021 | $4,512,000 | +14.5% | 206,126 | 0.0% | 1.90% | +36.5% |
Q3 2021 | $3,939,000 | +11.3% | 206,126 | 0.0% | 1.39% | -1.7% |
Q2 2021 | $3,539,000 | -38.0% | 206,126 | -19.2% | 1.41% | -31.3% |
Q1 2021 | $5,706,000 | -44.9% | 255,180 | -45.2% | 2.06% | -27.0% |
Q4 2020 | $10,353,000 | +191.4% | 465,500 | +93.4% | 2.82% | +191.9% |
Q3 2020 | $3,553,000 | -0.4% | 240,744 | 0.0% | 0.96% | -6.4% |
Q2 2020 | $3,568,000 | – | 240,744 | – | 1.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |